My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

3.410 +1.090 (+46.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations
Today, investors in Cassava Sciences and SAVA stock are seeing a lot of red, as investors digest a statement of concern filed yesterday. 
Via InvestorPlace
Mid-Afternoon Market Update: Dow Rises 100 Points; ScanSource Shares Surge Following Q4 Results
Toward the end of trading Wednesday, the Dow traded up 0.30% to 35,470.78 while the NASDAQ rose 0.12% to 15,038.45. The S&P also rose, gaining 0.28% to 4,498.64. The U.S. has... 
Via Benzinga
Topics Stocks
S&P 500, Nasdaq Extend Records on Delta Variant Decline
The S&P 500 Index and Nasdaq Composite are on the rise midday, extending yesterday's record closes and nabbing fresh intraday highs. 
Via Talk Markets
Topics Stocks
2 Little-Known Nasdaq Stocks Making Big Moves Wednesday
Don't let these companies fly under your radar. 
Via The Motley Fool
Topics Stocks
SAVA Stock: The Allegations That Have Cassava Sciences Sinking Today
Shares of SAVA stock are crashing on Wednesday after allegations about Cassava Sciences' Alzheimer's disease treatment are being reviewed. 
Via InvestorPlace
The Law Offices of Frank R. Cruz Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell Bioscience's stock is trading at a volume of 8... 
Via Benzinga
Mid-Day Market Update: Gold Down 1%; Locust Walk Acquisition Shares Jump
Midway through trading Wednesday, the Dow traded up 0.20% to 35,435.82 while the NASDAQ rose 0.05% to 15,027.49. The S&P also rose, gaining 0.14% to 4,492.54. The U.S. has the... 
Via Benzinga
Topics Stocks
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR... 
Via Benzinga
Here's Why Cassava Sciences Is Having a Bad Day
The FDA received a citizen petition requesting a halt to clinical trials with the company's Alzheimer's disease candidate. 
Via The Motley Fool
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views
Following the market opening Wednesday, the Dow traded up 0.07% to 35,389.32 while the NASDAQ rose 0.17% to 15,045.45. The S&P also rose, gaining 0.14% to 4,492.57. The U.S.... 
Via Benzinga
Topics Stocks
Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near
SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. 
Via InvestorPlace
Cassava Stock Plummets On Claims Of 'Data Manipulation' In Alzheimer's Testing
A shareholder firm called for the FDA to halt Cassava Sciences' studies in Alzheimer's disease, leading SAVA stock to plummet Wednesday. 
Via Investor's Business Daily
Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy
Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced... 
Via Benzinga
Why Cassava Sciences' Stock Is Getting Hammered Today
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 25.49% to $19.2 during Wednesday's pre-market session. The company's market cap stands at $242.7... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported... 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Cassava Sciences Has an Admirable Goal at Too High a Price
It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No. 
Via InvestorPlace
Cassava Sciences Receives FDA's Special Protocol Assessment For Alzheimer's Trials
Cassava Sciences Inc (NASDAQ: SAVA) announced an agreement with the FDA under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 trials for oral... 
Via Benzinga
Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth
With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits. 
Via InvestorPlace
Tread Carefully Before Pulling the Trigger on Cassava Sciences
While SAVA stock is intriguing based on the underlying Alzheimer’s treatment proposal, this market has an extremely high failure rate. 
Via InvestorPlace
Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk
SAVA stock has gone "to the moon" thanks to its Alzheimer treatment catalyst, but don't assume it's immune to a possible reversal. 
Via InvestorPlace
These Are the Top Reasons You Should Load Up on Cassava Sciences Stock
At the moment, there’s no cure for Alzheimer’s, but Cassava Sciences is working to wipe it out for good, making SAVA stock a buy here. 
Via InvestorPlace
With This Exciting Alzheimer’s Treatment, Cassava Sciences Stock Has Legs
Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock. 
Via InvestorPlace
Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug
Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock. 
Via InvestorPlace
< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.